Mabwell announced its wholly-owned subsidiary Mabwell Therapeutics has entered into an agreement with DISC MEDICINE, INC. (Disc) about 9MW3011 (R&D code in the US: MWTX-001, MWTX-002 & MWTX-003). Under the terms of the agreement, Disc will obtain exclusive rights to develop and commercialize 9MW3011 discovered by Mabwell, in the United States, Europe, and other territories outside of Great China and Southeast Asia. Mabwell can obtain a total of up to $412.5 million of down payment and milestone payment, and can also obtain the royalty of close to two digit percentage of net sales of licensed products, of which Disc will pay a one-time non refundable down payment of $10million to Mabwell.

9MW3011 has been approved by NMPA and FDA to carry out clinical trials in China and the United States respectively. The proposed indications of 9MW3011 include a variety of diseases classified as rare in different regions of the world, such as ß-thalassemia, polycythemia vera. There are no mature and effective macromolecular drugs for the relevant indications so far.

9MW3011 is expected to be qualified as an orphan drug in the future and become the first-in-class macromolecular drug to regulate iron homeostasis in vivo.